Phathom Pharmaceuticals (PHAT) Other Non-Current Assets (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Other Non-Current Assets data on file, last reported at $2.9 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $2.9 million, up 68.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 million (up 68.99% YoY), and the FY2025 annual result was $2.9 million, up 72.3% from the prior year.
• Other Non-Current Assets declined to $2.9 million in Q1 2026 per PHAT's latest filing, from $2.9 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $3.8 million in Q3 2023 and troughed at $299000.0 in Q4 2022.
• A 5-year average of $2.0 million and a median of $1.7 million in 2024 frame the typical range for Other Non-Current Assets.
• On a YoY basis, Other Non-Current Assets climbed as much as 467.72% in 2024 and fell as far as 54.87% in 2024.
• A 5-year view of Other Non-Current Assets shows it stood at $299000.0 in 2022, then jumped by 465.89% to $1.7 million in 2023, then advanced by 0.06% to $1.7 million in 2024, then jumped by 72.3% to $2.9 million in 2025, then declined by 1.92% to $2.9 million in 2026.
• Business Quant data shows PHAT's Other Non-Current Assets at $2.9 million in Q1 2026, $2.9 million in Q4 2025, and $2.9 million in Q3 2025.